Bone Cancer Clinical Trial
Official title:
Retrieved Allograft Study: Retrospective Study of the Biomechanical Properties of Large Allografts
Verified date | July 2012 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Primary Objectives:
1. To evaluate the material properties, histomorphometric indices, bone mineral density
(BMD), and presence of microfractures in retrieved large allograft cortical bone
specimens removed from orthopaedic oncology patients.
2. To correlate physical properties to patient demographics and medical treatment
received.
Status | Terminated |
Enrollment | 2 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients that require retrieval of a previously implanted large allograft. Exclusion Criteria: |
Observational Model: Case-Only, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
United States | U.T.M.D. Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | Musculoskeletal Transplant Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To learn about properties (such as bone strength, bone density, and new bone formation) of removed transplant tissue and how it integrated with participant's own tissues during the time it was implanted. | 3 Years | No | |
Secondary | To compare information such as the reasons this allograft was used and the length of time before it was removed to other patients who have received similar allograft tissues that were removed. | 3 Years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03905174 -
Massive Implants the Next Generation
|
N/A | |
Completed |
NCT00160719 -
HLA Sensitization Following Major Cortical Allograft Bone Procedures
|
Phase 4 | |
Completed |
NCT04974008 -
Osteosarcoma Maintenance Therapy With OST31-164
|
Phase 2 | |
Not yet recruiting |
NCT06070259 -
Insights Into Participating in Studies for Bone Cancer
|
||
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Active, not recruiting |
NCT02880319 -
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Terminated |
NCT00960063 -
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
|
Phase 1 | |
Terminated |
NCT02443103 -
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Terminated |
NCT03525392 -
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
|
Phase 1 | |
Terminated |
NCT01541358 -
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
|
N/A | |
Terminated |
NCT01313884 -
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
|
Phase 2 | |
Completed |
NCT01091883 -
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
|
N/A | |
Terminated |
NCT00127387 -
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03106675 -
MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases
|
N/A | |
Recruiting |
NCT05830084 -
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
|
Phase 1 | |
Completed |
NCT01085565 -
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
|
Phase 2 | |
Recruiting |
NCT04307914 -
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases
|
N/A |